S066 Advanced Therapeutics for Complex Dermatologic Disease
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
The skin is a window into the inner workings of the immune system and the rest of the body. As dermatologists, we play a critical role in diagnosis and management, but often require the help of other specialties to treat complex disease. In this session, we hope to demystify the systemic therapeutics that are often used in treatment of complex skin disease, and in areas where appropriate, will demonstrate how dermatologists can reclaim the management of systemic disease.
We will also highlight research on new adverse effects for systemic medications, as well as novel treatment paradigms in our specialty.
LEARNING OBJECTIVES
Develop treatment algorithms for complex medical dermatologic conditions, namely: connective tissue diseases, blistering disorders, neutrophilic dermatoses, hidradenitis suppurativa, GVHD, and oncodermatologic conditions.
Manage complications that may arise as a result of systemic therapeutic options prescribed by the dermatologist.
Discuss our new understanding of pathophysiologic mechanisms that may impact adverse effects and open new treatment paradigms.
SCHEDULE
5:00 PM
Connective Tissue Diseases
Janice Tiao, MD, FAAD
5:30 PM
Update on Cutaneous Graft-vs-Host Disease
Michael Stephens, MD, FAAD
6:00 PM
TBD
Helena Beth Pasieka, MD
6:30 PM
Pearls and Pitfalls in the treatment of SCARs and irAEs
Steven T. Chen, MD, MPH, FAAD
7:00 PM
Update on Hidradenitis Suppurativa
Madeline DeWane, MD, FAAD
7:30 PM
Neutrophilic Dermatoses
Misha Rosenbach, MD, FAAD
SPEAKERS
Steven T. Chen, MD, MPH, FAAD
Madeline DeWane, MD, FAAD
Helena Beth Pasieka, MD
Misha Rosenbach, MD, FAAD
Michael Stephens, MD, FAAD
Janice Tiao, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Steven T. Chen, MD, MPH, FAAD
Vertex Pharmaceuticals Incorporated – Employee (w-2 relationship)(Salary); VisualDx – Independent Contractor(Fees);
Madeline DeWane, MD, FAAD
VeraDermics Inc. – Founder(No Compensation Received);
Helena Beth Pasieka, MD
No financial relationships exist with ineligible companies.
Misha Rosenbach, MD, FAAD
J&J Innovative Medicine – Consultant(Honoraria); Merck & Co., Inc – Consultant(Honoraria); Novartis – Consultant(Honoraria); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria);
Michael Stephens, MD, FAAD
No financial relationships exist with ineligible companies.
Janice Tiao, MD, FAAD
No financial relationships exist with ineligible companies.